Supplementary Figure S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

The Kaplan-Meier curve of progress-free PFS in the Per-Protocol Set. The tick marks indicate censored data.</p

Supplementary Table S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Multivariable Cox regression analysis of determinants of OS (without consideration of crossover)</p

Supplementary Figure S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

(A) Kaplan–Meier estimate of progress-free survival (PFS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 3 months before enrollment. (C) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of PFS in patients who had radiographic progressive disease beyond 12 months before enrollment. The tick marks indicate censored data.</p

Supplementary Table S4 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Grade 3 or above treatment-related adverse events (TRAEs)</p

Supplementary Table S2 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Multivariable Cox regression analysis of determinants of PFS</p

Supplementary Figure S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Best changes in the sum of longest diameters of target lesions for the anlotinib group and the placebo group. Purplish red: confirmed partial response; blue: stable disease lasting at least 4 week.</p

Supplementary Figure S3 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

(A) Kaplan–Meier estimate of overall survival (OS) in patients who had radiographic progressive disease within 3 months before enrollment. (B) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 3 months before enrollment. (C) Kaplan–Meier estimate of OS in patients who had radiographic progressive disease within 12 months before enrollment. (D) Kaplan–Meier estimate of OS in patients who had no radiographic progressive disease within 12 months before enrollment. The tick marks indicate censored data.</p

Supplementary Table S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Representativeness of Study Participants</p

Supplementary Table S5 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Changes of quality of life throughout the treatment period evaluated by EORTC QLQ-C30.</p

Supplementary Methods S1 from Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial

Supplementary methods</p